FDA NDA 215256, WEGOVY, NOVO, 06/04/2021

Contents: Summary Basis of Approval (SBA) documents for Wegovy (semaglutide), NDA 215256/S-11

NDA: 215256
Company: NOVO
Drug Name: WEGOVY
Active Ingredients: SEMAGLUTIDE
Strength: 2.4MG/0.75ML (2.4MG/0.75ML)
Dosage Form/Route: SOLUTION;SUBCUTANEOUS
Action Date: 06/04/2021
Marketing Status: Prescription
Submission Classification: ORIG-1

300 Pages

PUBLICLY AVAILABLE (we charge a convenience fee for download)